Nordic Nanovector to Update Data on Betalutin in Non-Hodgkin’s Lymphoma Trial at June Meeting
News
Nordic Nanovector will present new data from the Phase 1/2 trial (NCT01796171) of its investigational treatment Betalutin for relapsed or treatment-resistant non-Hodgkin’s lymphoma at the International Conference on Malignant Lymphoma, ... Read more